Nanotechnology Stocks To Keep An Eye On – February 03rd

OSI Systems, NVE, Clene, Virpax Pharmaceuticals, and Biodexa Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are stocks of companies that are involved in the research, development, manufacturing, or commercialization of products and technologies that are based on nanoscale materials and processes. These stocks are typically focused on leveraging the unique properties of nanoparticles and nanomaterials for applications in various industries, such as electronics, healthcare, energy, and materials science. Investors interested in the potential growth and impact of nanotechnology often consider investing in these stocks for exposure to this evolving and disruptive field. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

OSIS traded down $2.34 during trading hours on Monday, hitting $194.10. 220,181 shares of the company’s stock were exchanged, compared to its average volume of 224,705. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56. OSI Systems has a 12-month low of $126.57 and a 12-month high of $201.42. The firm has a market cap of $3.26 billion, a P/E ratio of 24.93, a price-to-earnings-growth ratio of 1.66 and a beta of 1.19. The firm has a 50 day moving average of $175.66 and a 200 day moving average of $155.93.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Shares of NASDAQ NVEC traded down $1.34 during mid-day trading on Monday, hitting $69.32. The company had a trading volume of 16,452 shares, compared to its average volume of 28,877. NVE has a 1-year low of $67.35 and a 1-year high of $90.24. The company has a market capitalization of $335.51 million, a PE ratio of 22.36 and a beta of 1.11. The business’s 50-day simple moving average is $78.70 and its 200 day simple moving average is $79.21.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

NASDAQ:CLNN traded down $0.13 during mid-day trading on Monday, hitting $4.37. The stock had a trading volume of 18,418 shares, compared to its average volume of 67,290. The company has a market capitalization of $36.01 million, a PE ratio of -0.83 and a beta of 0.24. The stock has a 50-day simple moving average of $4.75 and a two-hundred day simple moving average of $5.05. Clene has a twelve month low of $3.82 and a twelve month high of $10.65.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

NASDAQ:VRPX traded down $0.03 during trading hours on Monday, hitting $0.29. The company’s stock had a trading volume of 211,403 shares, compared to its average volume of 508,376. The stock has a fifty day moving average of $0.36 and a 200-day moving average of $0.66. Virpax Pharmaceuticals has a 52-week low of $0.23 and a 52-week high of $5.48.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of NASDAQ BDRX traded down $0.11 during midday trading on Monday, hitting $4.30. 2,287 shares of the company’s stock were exchanged, compared to its average volume of 13,263. The firm has a fifty day simple moving average of $4.49. Biodexa Pharmaceuticals has a twelve month low of $3.50 and a twelve month high of $74.00.